The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoring.
Despite being among the most potent protease inhibitors, the use of tipranavir (TPV) is hampered by a high pill burden and frequent side effects compared with other boosted protease inhibitors. A total of 10 patients receiving TPV/ritonavir (TPV/RTV) 500/200 for longer than 6 months were randomized to stay on the same dosing schedule or switch to TPV/RTV 500/100. Although all patients on TVP/RTV 500/200 remained stable for the next 12 weeks, 3 out of 5 patients who switched doses experienced benefits in terms of reducing aminotransferases and total cholesterol. Fasting triglycerides were also reduced in 2 of them. Plasma HIV-RNA remained undetectable in all patients, despite the observed decline in TPV trough concentrations.
Morello
Judit
J
Pharmacokinetic Unit, Hospital Carlos III, Madrid, Spain.
Rodríguez-Novoa
Sonia
S
Blanco
Francisco
F
Vispo
Eugenia
E
Barreiro
Pablo
P
Gonzalez-Pardo
Gema
G
Jiménez-Nácher
Inmaculada
I
González-Lahoz
Juan
J
Soriano
Vincent
V
D000328:Adult; D004334:Drug Administration Schedule; D016903:Drug Monitoring / Q000379:methods / Q000592:standards*; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011725:Pyridines / Q000008:administration & dosage* / Q000097:blood*; D011753:Pyrones / Q000008:administration & dosage* / Q000097:blood*; D019438:Ritonavir / Q000008:administration & dosage* / Q000097:blood*; D013449:Sulfonamides
D011725:Pyridines; D011753:Pyrones; D013449:Sulfonamides; D019438:Ritonavir; C107201:tipranavir